ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

LYEL Lyell Immunopharma Inc

2.135
-0.225 (-9.53%)
Última actualización: 14:02:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lyell Immunopharma Inc LYEL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.225 -9.53% 2.135 14:02:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.33 2.13 2.35 2.36
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202415:07EDGAR2Form 8-K - Current report
03/6/202415:05GLOBELyell Immunopharma to Participate in the Goldman Sachs..
07/5/202415:05GLOBELyell Immunopharma to Participate in BofA Securities Health..
06/5/202407:12EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/5/202407:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202407:03EDGAR2Form 8-K - Current report
06/5/202407:00GLOBELyell Immunopharma Reports Business Highlights and Financial..
05/3/202415:30GLOBELyell Immunopharma Announces the Acceptance of Three..
28/2/202415:07EDGAR2Form 8-K - Current report
28/2/202415:05GLOBELyell Immunopharma Reports Business Highlights and Financial..
26/2/202415:05GLOBELyell Immunopharma Announces Participation in March Investor..
13/2/202419:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202419:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202419:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:05GLOBELyell Immunopharma to Participate in 42nd Annual J.P. Morgan..
20/11/202319:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202319:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202319:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202315:26EDGAR2Form 8-K - Current report
09/11/202315:05GLOBELyell Immunopharma Receives FDA Orphan Drug Designation for..
07/11/202315:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202315:08EDGAR2Form 8-K - Current report
07/11/202315:05GLOBELyell Immunopharma Reports Business Highlights and Financial..
31/10/202308:00GLOBELyell Immunopharma Presentations at SITC Highlight New..
27/9/202308:00GLOBELyell Immunopharma Announces the Acceptance of Six Abstracts..
11/9/202308:16EDGAR2Form 8-K - Current report
11/9/202307:00GLOBECellares and Lyell to Evaluate Automated Manufacturing of..
31/8/202315:05GLOBELyell Immunopharma to Participate in Upcoming Investor..
08/8/202315:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:10EDGAR2Form 8-K - Current report
08/8/202315:05GLOBELyell Immunopharma Reports Business Highlights and Financial..
05/7/202315:05GLOBELyell Immunopharma Appoints Matthew Lang as Chief Business..